Evidence map›Paper›PMID 15208742›Full record

ArticleMolecular medicine (Cambridge, Mass.)

In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals.

Leo Kei Iwai, Márcia Yoshida, John Sidney, Maria Aparecida Shikanai-Yasuda, Anna Carla Goldberg, Maria Aparecida Juliano, Jurgen Hammer, Luiz Juliano, Alessandro Sette, Jorge Kalil and 2 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Molecular medicine (Cambridge, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 92 citations in OpenAlex.

  1. Article
  2. Epitope mapping ofHeliyon · 2023
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Dendritic Cells Primed withFrontiers in microbiology · 2017
    Article
  14. Article
  15. Linear Epitopes ofFrontiers in immunology · 2017
    Review
  16. Article
  17. Immunogenic peptide discovery in cancer genomes.Current opinion in genetics & development · 2015
    Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Leo Kei IwaiLaboratory of Immunology, Heart Institute (Incor), Millenium Institutes, Brazil.
Márcia Yoshida
John Sidney
Maria Aparecida Shikanai-Yasuda
Anna Carla Goldberg
Maria Aparecida Juliano
Jurgen Hammer
Luiz Juliano
Alessandro Sette
Jorge Kalil
Luiz Rodolpho Travassos
Edecio Cunha-Neto
Universidade de São Paulo · BRUniversidade Federal de São Paulo · BRLa Jolla Institute for Immunology · USLa Roche College · USMillennium Institute · BR

Funding

BAA-APPLICATION OF HLA DATA TO DEVELOP &IMPROVE VACCINEN01AI095362 · NIAID · IDM PHARMA, INC. · PI SETTE, ALESSANDRO · 1999 to 2000
$449k
AHRQ HHS HHSN266200400006CNIAID NIH HHS N01 AI095362NIAID NIH HHS N01-AI-95362
6 · The paper itself

Abstract

One of the major drawbacks limiting the use of synthetic peptide vaccines in genetically distinct populations is the fact that different epitopes are recognized by T cells from individuals displaying distinct major histocompatibility complex molecules. Immunization of mice with peptide (181-195) from the immunodominant 43 kDa glycoprotein of Paracoccidioides brasiliensis (gp43), the causative agent of Paracoccidioidomycosis (PCM), conferred protection against infectious challenge by the fungus. To identify immunodominant and potentially protective human T-cell epitopes in gp43, we used the TEPITOPE algorithm to select peptide sequences that would most likely bind multiple HLA-DR molecules and tested their recognition by T cells from sensitized individuals. The 5 most promiscuous peptides were selected from the gp43 sequence and the actual promiscuity of HLA binding was assessed by direct binding assays to 9 prevalent HLA-DR molecules. Synthetic peptides were tested in proliferation assays with peripheral blood mononuclear cells (PBMC) from PCM patients after chemotherapy and healthy controls. PBMC from 14 of 19 patients recognized at least one of the promiscuous peptides, whereas none of the healthy controls recognized the gp43 promiscuous peptides. Peptide gp43(180-194) was recognized by 53% of patients, whereas the other promiscuous gp43 peptides were recognized by 32% to 47% of patients. The frequency of peptide binding and peptide recognition correlated with the promiscuity of HLA-DR binding, as determined by TEPITOPE analysis. In silico prediction of promiscuous epitopes led to the identification of naturally immunodominant epitopes recognized by PBMC from a significant proportion of a genetically heterogeneous patient population exposed to P. brasiliensis. The combination of several such epitopes may increase the frequency of positive responses and allow the immunization of genetically distinct populations.

Indexed as

Immunodominant EpitopesAlgorithmsAntigens, FungalCD4-Positive T-LymphocytesCell DivisionCohort StudiesEnzyme-Linked Immunosorbent AssayEpitopes, T-LymphocyteFungal ProteinsGlycoproteinsHLA-DR AntigensHumansImmunoblottingLeukocytes, MononuclearParacoccidioidesParacoccidioidomycosis43 kDa protein, ParacoccidioidesAntigens, FungalEpitopes, T-LymphocyteFungal ProteinsGlycoproteinsHLA-DR AntigensImmunodominant EpitopesPeptides

Identifiers

PMID15208742
PMCPMC1430984
OpenAlexW2244240891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.